Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Castagnoli L, Cancila V, Cordoba-Romero SL, Faraci S, Talarico G, Belmonte B, Iorio MV, Milani M, Volpari T, Chiodoni C, Hidalgo-Miranda A, Tagliabue E, Tripodo C, Sangaletti S, Di Nicola M, Pupa SM.

Oncogene. 2019 Jan 31. doi: 10.1038/s41388-019-0700-2. [Epub ahead of print]

PMID:
30705400
2.

Time for a "Plan B" in Peritoneal Metastatic Disease.

Tripodo C.

Cancer Res. 2019 Jan 1;79(1):5-6. doi: 10.1158/0008-5472.CAN-18-3553.

PMID:
30602622
3.

Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming.

Simula L, Pacella I, Colamatteo A, Procaccini C, Cancila V, Bordi M, Tregnago C, Corrado M, Pigazzi M, Barnaba V, Tripodo C, Matarese G, Piconese S, Campello S.

Cell Rep. 2018 Dec 11;25(11):3059-3073.e10. doi: 10.1016/j.celrep.2018.11.018.

4.

Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.

Fortunato O, Borzi C, Milione M, Centonze G, Conte D, Boeri M, Verri C, Moro M, Facchinetti F, Andriani F, Roz L, Caleca L, Huber V, Cova A, Camisaschi C, Castelli C, Cancila V, Tripodo C, Pastorino U, Sozzi G.

Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31988. [Epub ahead of print]

PMID:
30426475
5.

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C.

Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8.

PMID:
30407629
6.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
7.

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.

Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A, Motta G, Rossi M, Agostinelli C, Sabattini E, Pimpinelli N, Truni M, Falini B, Cerroni L, Talarico G, Piccioni R, Amente S, Indio V, Tarantino G, Brundu F, Paulli M, Berti E, Facchetti F, Dellino GI, Bertolini F, Tripodo C, Rabadan R, Pileri SA.

Haematologica. 2018 Oct 31. pii: haematol.2018.202093. doi: 10.3324/haematol.2018.202093. [Epub ahead of print]

8.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Dec 1;29(12):2363-2370. doi: 10.1093/annonc/mdy450.

9.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
10.

Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.

Mangogna A, Belmonte B, Agostinis C, Ricci G, Gulino A, Ferrara I, Zanconati F, Tripodo C, Romano F, Kishore U, Bulla R.

Front Immunol. 2018 Aug 6;9:1748. doi: 10.3389/fimmu.2018.01748. eCollection 2018.

11.

Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth.

Pacella I, Cammarata I, Focaccetti C, Miacci S, Gulino A, Tripodo C, Ravà M, Barnaba V, Piconese S.

Cancer Immunol Res. 2018 Aug;6(8):953-964. doi: 10.1158/2326-6066.CIR-17-0713. Epub 2018 Jul 17.

PMID:
30018042
12.

Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.

Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP.

Cancer Immunol Res. 2018 May;6(5):552-565. doi: 10.1158/2326-6066.CIR-17-0385. Epub 2018 Mar 9.

PMID:
29523597
13.

Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence.

Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, Colombo M, Emionite L, Sangaletti S, Gulino A, Reverberi D, Massara R, Boccardo S, de Totero D, Salvi S, Cilli M, Pellicanò M, Manzoni M, Fabris S, Airoldi I, Valdora F, Ferrini S, Gentile M, Vigna E, Bossio S, De Stefano L, Palummo A, Iaquinta G, Cardillo M, Zupo S, Cerruti G, Ibatici A, Neri A, Fais F, Ferrarini M, Morabito F.

Sci Transl Med. 2018 Feb 14;10(428). pii: eaal1571. doi: 10.1126/scitranslmed.aal1571.

PMID:
29444977
14.

IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Ferretti E, Di Carlo E, Ognio E, Fraternali-Orcioni G, Corcione A, Belmonte B, Ravetti JL, Tripodo C, Ribatti D, Pistoia V.

Oncoimmunology. 2017 Nov 27;7(3):e1397249. doi: 10.1080/2162402X.2017.1397249. eCollection 2018.

15.

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8.

Ah Kioon MD, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK, Gordon JK, Barrat FJ.

Sci Transl Med. 2018 Jan 10;10(423). pii: eaam8458. doi: 10.1126/scitranslmed.aam8458.

PMID:
29321259
16.

Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.

Vacca D, Cancila V, Gulino A, Lo Bosco G, Belmonte B, Di Napoli A, Florena AM, Tripodo C, Arancio W.

Mol Biol Rep. 2018 Feb;45(1):1-7. doi: 10.1007/s11033-017-4133-0. Epub 2017 Dec 13.

PMID:
29238890
17.

Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth.

Agostinis C, Vidergar R, Belmonte B, Mangogna A, Amadio L, Geri P, Borelli V, Zanconati F, Tedesco F, Confalonieri M, Tripodo C, Kishore U, Bulla R.

Front Immunol. 2017 Nov 20;8:1559. doi: 10.3389/fimmu.2017.01559. eCollection 2017.

18.

Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.

Anania MC, Cetti E, Lecis D, Todoerti K, Gulino A, Mauro G, Di Marco T, Cleris L, Pagliardini S, Manenti G, Belmonte B, Tripodo C, Neri A, Greco A.

Cancer Lett. 2017 Dec 1;410:201-211. doi: 10.1016/j.canlet.2017.09.024. Epub 2017 Sep 23.

PMID:
28951131
19.

Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer.

Mion F, Vetrano S, Tonon S, Valeri V, Piontini A, Burocchi A, Petti L, Frossi B, Gulino A, Tripodo C, Colombo MP, Pucillo CE.

Oncoimmunology. 2017 Jun 19;6(8):e1336593. doi: 10.1080/2162402X.2017.1336593. eCollection 2017.

20.

Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities.

Miotti S, Gulino A, Ferri R, Parenza M, Chronowska A, Lecis D, Sangaletti S, Tagliabue E, Tripodo C, Colombo MP.

FASEB J. 2017 Dec;31(12):5356-5370. doi: 10.1096/fj.201700377R. Epub 2017 Aug 8.

PMID:
28790175
21.

The good and bad of targeting cancer-associated extracellular matrix.

Sangaletti S, Chiodoni C, Tripodo C, Colombo MP.

Curr Opin Pharmacol. 2017 Aug;35:75-82. doi: 10.1016/j.coph.2017.06.003. Epub 2017 Jul 19. Review.

PMID:
28734136
22.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.

Rossini A, Zunino F, Ruggiero G, De Cesare M, Cominetti D, Tortoreto M, Lanzi C, Cassinelli G, Zappasodi R, Tripodo C, Gulino A, Zaffaroni N, Di Nicola M.

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21. No abstract available.

PMID:
28730742
23.

Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.

Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C.

Clin Cancer Res. 2017 Sep 1;23(17):5149-5161. doi: 10.1158/1078-0432.CCR-16-3186. Epub 2017 Jun 9.

24.

Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling.

Tripodo C, Burocchi A, Piccaluga PP, Chiodoni C, Portararo P, Cappetti B, Botti L, Gulino A, Isidori A, Liso A, Visani G, Martelli MP, Falini B, Pandolfi PP, Colombo MP, Sangaletti S.

Cancer Res. 2017 Jul 1;77(13):3685-3699. doi: 10.1158/0008-5472.CAN-17-1098. Epub 2017 May 23.

25.

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.

Piccaluga PP, Agostinelli C, Righi S, Ciccone M, Re MC, Musumeci G, Diani E, Signoretto C, Bon I, Piccin O, Cuneo A, Tripodo C, Ponti C, Zipeto D, Landolfo S, Gibellini D.

APMIS. 2017 Jun;125(6):511-522. doi: 10.1111/apm.12692. Epub 2017 May 18.

PMID:
28517553
26.

Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments.

Sangaletti S, Chiodoni C, Tripodo C, Colombo MP.

Cancer Immunol Immunother. 2017 Aug;66(8):1059-1067. doi: 10.1007/s00262-017-2014-y. Epub 2017 May 13. Review.

PMID:
28501940
27.

Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses.

Frossi B, Mion F, Tripodo C, Colombo MP, Pucillo CE.

Trends Immunol. 2017 Sep;38(9):648-656. doi: 10.1016/j.it.2017.04.001. Epub 2017 Apr 25. Review.

PMID:
28462845
28.

Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.

Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Döring C, Rossi M, Melle F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Gazzola A, Mannu C, Sagramoso CA, Lonardi S, Lorenzi L, Bacci F, Sabattini E, Borges A, Simonitsch-Klupp I, Cabecadas J, Campo E, Rosai J, Hansmann ML, Facchetti F, Pileri SA.

Mol Cancer Res. 2017 May;15(5):541-552. doi: 10.1158/1541-7786.MCR-16-0301. Epub 2017 Jan 27.

29.

Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.

Jachetti E, Rigoni A, Bongiovanni L, Arioli I, Botti L, Parenza M, Cancila V, Chiodoni C, Festinese F, Bellone M, Tardanico R, Tripodo C, Colombo MP.

Mol Cancer Ther. 2017 Feb;16(2):365-375. doi: 10.1158/1535-7163.MCT-16-0466. Epub 2016 Dec 15.

30.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
31.

Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.

Sangaletti S, Tripodo C, Santangelo A, Castioni N, Portararo P, Gulino A, Botti L, Parenza M, Cappetti B, Orlandi R, Tagliabue E, Chiodoni C, Colombo MP.

Cell Rep. 2016 Sep 27;17(1):233-248. doi: 10.1016/j.celrep.2016.08.075.

32.

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.

Romano A, Parrinello NL, Vetro C, Tibullo D, Giallongo C, La Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, Di Raimondo F.

Oncotarget. 2016 Oct 11;7(41):67333-67346. doi: 10.18632/oncotarget.12024.

33.

Mast cells are associated with the onset and progression of celiac disease.

Frossi B, Tripodo C, Guarnotta C, Carroccio A, De Carli M, De Carli S, Marino M, Calabrò A, Pucillo CE.

J Allergy Clin Immunol. 2017 Apr;139(4):1266-1274.e1. doi: 10.1016/j.jaci.2016.08.011. Epub 2016 Sep 13.

PMID:
27619824
34.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

35.

MEF2C and SOCS2 in stemness regulation.

Vitali C, Tripodo C, Colombo MP.

Oncoscience. 2015 Dec 28;2(12):936-7. eCollection 2015. No abstract available.

36.

C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnotta C, Zorzet S, Durigutto P, Botto M, Tedesco F.

Nat Commun. 2016 Feb 1;7:10346. doi: 10.1038/ncomms10346.

37.

Mast cells contribute to autoimmune diabetes by releasing interleukin-6 and failing to acquire a tolerogenic IL-10+ phenotype.

Betto E, Usuelli V, Mandelli A, Badami E, Sorini C, Capolla S, Danelli L, Frossi B, Guarnotta C, Ingrao S, Tripodo C, Pucillo C, Gri G, Falcone M.

Clin Immunol. 2017 May;178:29-38. doi: 10.1016/j.clim.2015.12.013. Epub 2015 Dec 28.

PMID:
26732858
38.

Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.

Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, Sangaletti S, Di Carlo E, Tripodo C, Colombo MP.

Oncotarget. 2016 Jan 26;7(4):3905-20. doi: 10.18632/oncotarget.6678.

39.

A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q- syndrome.

Arancio W, Genovese SI, Bongiovanni L, Tripodo C.

Oncoscience. 2015 Nov 11;2(10):872-9. eCollection 2015.

40.

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.

Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, Cammà C, Cappon A, Di Marco V, Di Maira G, Dongiovanni P, Rametta R, Gulino A, Mozzi E, Orlando E, Maggioni M, Pipitone RM, Fargion S, Craxì A.

J Hepatol. 2016 Mar;64(3):682-90. doi: 10.1016/j.jhep.2015.10.016. Epub 2015 Oct 24.

41.

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.

Le Noci V, Tortoreto M, Gulino A, Storti C, Bianchi F, Zaffaroni N, Tripodo C, Tagliabue E, Balsari A, Sfondrini L.

Oncoimmunology. 2015 May 27;4(10):e1040214. eCollection 2015 Oct.

42.

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, Tripodo C, Pistoia V.

Oncoimmunology. 2015 Jun 19;4(10):e1030560. eCollection 2015 Oct.

43.

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.

Felli N, Errico MC, Pedini F, Petrini M, Puglisi R, Bellenghi M, Boe A, Felicetti F, Mattia G, De Feo A, Bottero L, Tripodo C, Carè A.

Oncogene. 2016 Jun 9;35(23):3016-26. doi: 10.1038/onc.2015.357. Epub 2015 Oct 5.

44.

Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.

Piccaluga PP, Navari M, De Falco G, Ambrosio MR, Lazzi S, Fuligni F, Bellan C, Rossi M, Sapienza MR, Laginestra MA, Etebari M, Rogena EA, Tumwine L, Tripodo C, Gibellini D, Consiglio J, Croce CM, Pileri SA, Leoncini L.

Oncotarget. 2016 Jan 5;7(1):224-40. doi: 10.18632/oncotarget.4399.

45.

RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.

Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, Porta C, Anselmo A, Tartari S, Doni A, Zitelli F, Tripodo C, Colombo MP, Sica A.

Cancer Cell. 2015 Aug 10;28(2):253-69. doi: 10.1016/j.ccell.2015.07.006.

46.

Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth.

Rigoni A, Bongiovanni L, Burocchi A, Sangaletti S, Danelli L, Guarnotta C, Lewis A, Rizzo A, Silver AR, Tripodo C, Colombo MP.

Cancer Res. 2015 Sep 15;75(18):3760-70. doi: 10.1158/0008-5472.CAN-14-3767. Epub 2015 Jul 23.

47.

IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation.

Piccaluga PP, Agostinelli C, Fuligni F, Righi S, Tripodo C, Re MC, Clò A, Miserocchi A, Morini S, Gariglio M, Ferri GG, Rinaldi-Ceroni A, Piccin O, De Andrea M, Pileri SA, Landolfo S, Gibellini D.

J Immunol Res. 2015;2015:747645. doi: 10.1155/2015/747645. Epub 2015 Jun 22.

48.

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.

Capolla S, Garrovo C, Zorzet S, Lorenzon A, Rampazzo E, Spretz R, Pozzato G, Núñez L, Tripodo C, Macor P, Biffi S.

Int J Nanomedicine. 2015 Jun 22;10:4099-109. doi: 10.2147/IJN.S78995. eCollection 2015.

49.

The ins and outs of osteopontin.

Chiodoni C, Sangaletti S, Tripodo C, Colombo MP.

Oncoimmunology. 2015 Apr 2;4(3):e978711. eCollection 2015 Mar.

50.

SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias.

Vitali C, Bassani C, Chiodoni C, Fellini E, Guarnotta C, Miotti S, Sangaletti S, Fuligni F, De Cecco L, Piccaluga PP, Colombo MP, Tripodo C.

Cancer Res. 2015 Jun 1;75(11):2387-99. doi: 10.1158/0008-5472.CAN-14-3625. Epub 2015 Apr 9.

Supplemental Content

Loading ...
Support Center